Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Sells 22,935 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $20.77, for a total value of $476,359.95. Following the completion of the sale, the insider now owns 4,402,849 shares in the company, valued at $91,447,173.73. The trade was a 0.52 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Entrada Therapeutics Trading Down 8.9 %

Shares of TRDA opened at $18.12 on Friday. The firm has a fifty day simple moving average of $18.39 and a two-hundred day simple moving average of $16.60. The firm has a market cap of $678.05 million, a PE ratio of 11.40 and a beta of -0.18. Entrada Therapeutics, Inc. has a 1-year low of $11.35 and a 1-year high of $21.79.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of TRDA. Janus Henderson Group PLC boosted its holdings in shares of Entrada Therapeutics by 10.5% in the third quarter. Janus Henderson Group PLC now owns 1,711,459 shares of the company’s stock worth $27,358,000 after buying an additional 161,962 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Entrada Therapeutics by 8.8% during the 3rd quarter. Geode Capital Management LLC now owns 576,451 shares of the company’s stock valued at $9,214,000 after acquiring an additional 46,512 shares during the period. State Street Corp increased its stake in shares of Entrada Therapeutics by 5.5% in the 3rd quarter. State Street Corp now owns 469,601 shares of the company’s stock worth $7,504,000 after purchasing an additional 24,385 shares in the last quarter. American Century Companies Inc. raised its holdings in Entrada Therapeutics by 5.1% in the 2nd quarter. American Century Companies Inc. now owns 384,973 shares of the company’s stock worth $5,486,000 after purchasing an additional 18,625 shares during the period. Finally, Jacobs Levy Equity Management Inc. lifted its position in Entrada Therapeutics by 50.3% during the third quarter. Jacobs Levy Equity Management Inc. now owns 201,803 shares of the company’s stock valued at $3,225,000 after purchasing an additional 67,559 shares in the last quarter. Institutional investors own 86.39% of the company’s stock.

Analysts Set New Price Targets

TRDA has been the subject of several recent analyst reports. Roth Mkm started coverage on Entrada Therapeutics in a research report on Thursday, December 5th. They issued a “buy” rating and a $29.00 price target for the company. Roth Capital upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Oppenheimer raised their price target on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday, November 6th. Finally, HC Wainwright upped their price objective on Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.